Previous Article | Next Article 
Journal of Clinical Microbiology, August 1998, p. 2396-2396, Vol. 36, No. 8
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
LETTERS TO THE EDITOR
Isolation of a Clostridium Exotoxin Producer Other
than Clostridium difficile from a Patient with Diarrhea
 |
LETTER |
Clostridium difficile-associated diarrhea is a
significant problem in many hospitals and chronic care facilities
(2). When established in the colon, pathogenic strains of
C. difficile produce toxins that cause diarrhea and
colitis; strains that do not produce toxins are not pathogenic. Toxin A
(molecular mass, 308 kDa) acts as an enterotoxin, while toxin B
(molecular mass, 250 to 270 kDa) acts as a cytotoxin (3),
and both toxins may act synergistically in vivo.
We report a case of isolation of a Clostridium sp. other
than C. difficile that produced A and B toxins from an
elderly patient belonging to a group of 17 subjects with diarrhea who
were admitted to the same room of the orthopedics unit and all treated
with ceftriaxone for 7 to 10 days of prophylaxis before operation. Diarrhea in this group of patients lasted for 20 days, but the patients
were not simultaneously affected. Stool samples from all patients were
collected in clear containers and screened for exotoxins A and B by a
commercially available enzyme immunoassay (Ridascreen C. difficile toxin A, B; R-Biopharm, Darmstadt, Germany). Swabs
of stool specimen from each patient were transported in an anaerobic
system (Port-A-Cul; BBL) and inoculated onto C. difficile selective agar plates (Oxoid) prepared in-house. The
plates were then incubated anaerobically for 48 to 72 h at
35°C. Colonies were identified as Clostridium by
colonial morphology, Gram's stain, and biochemical profile (API 20 A
anaerobe and Vitek ANI systems; bio-Merieux).
Out of samples from 17 patients, toxins A and B were detected at
different times in the stools of only 8 patients, but no C. difficile was isolated. In our experience, this is very unusual, because we generally isolate C. difficile from
stools with toxins A and B. For the last 3 of the 17 patients we therefore considered all the clostridia isolated, namely,
C. paraputrificum, C. baratii, C. tertium, C. bifermentans,
C. innocuum, C. clostridiiforme, and C. sporogenes. After identification the clostridium
strains were cultured and stored, before being checked for the presence of toxigenic products, in Bactec plus anaerobic vials (Becton Dickinson) containing liquid medium and matrix with fluorescent material that reacts to CO2 produced by bacteria. This
reaction, as measured by the photodetectors of an instrument, is
evidence of bacterial growth. We chose this method because
the bacterial culture is performed outside an anaerobic chamber and we
observed (unpublished observation) that the production of bacterial
exotoxins may be predicted by the black coloring of matrix at the
bottom of the vials. Indeed, the bacterial cultures of nontoxigenic
strains produced no change in color and the matrix remained brown,
while exotoxin-producing strains changed the matrix to black.
Only in one of the last three patients considered did we identify a
strain of C. baratii producing exotoxins A and B. Cultures of this microorganism were positive for A and B exotoxin
production by enzyme immunoassay and for cytotoxin B by tissue culture
assay using Vero cells and C. difficile antitoxin B
(Biolife) as a control. After the addition of a 0.5-ml inoculum (0.5 McFarland) in 30 ml of liquid medium, C. difficile ATCC
9689 produced black coloring of the matrix in 3 days while
C. baratii produced black coloring in 8 days. This Clostridium sp. was positive for C. difficile antigens by a latex agglutination test (Meridian
Diagnostics Inc.), but its biochemical profile and gas chromatography
results were different from those of C. difficile ATCC
9689 and similar to those of a C. baratii toxin
nonproducer. For toxigenic C. baratii tested by an
agar dilution method (4), the MICs of teicoplanin and
metronidazole were 1 and 8 mg/liter, respectively. The patients with
diarrhea were treated at first with metronidazole without success and
later with teicoplanin. This experience suggests that
Clostridium microorganisms other than C. difficile sometimes produce A and B toxins but also that
C. baratii, which is reported as a botulinal toxin
producer (1, 5), is capable of toxin A and B production.
 |
REFERENCES |
| 1.
|
Hatheway, C. L., and L. M. McCroskey.
1987.
Examination of feces and serum for diagnosis of infant botulism in 336 patients.
J. Clin. Microbiol.
25:2334-2338[Abstract/Free Full Text].
|
| 2.
|
Johnson, S.,
C. R. Clabols,
F. V. Lin,
M. M. Olson,
L. R. Peterson, and D. N. Gerding.
1990.
Nosocomial Clostridium difficile colonization and disease.
Lancet
336:97-100[Medline].
|
| 3.
|
Lyerly, D. M.,
H. C. Krivan, and T. D. Wilkins.
1988.
Clostridium difficile: its disease and toxins.
Clin. Microbiol. Rev.
1:1-18[Abstract/Free Full Text].
|
| 4.
|
National Committee for Clinical Laboratory Standards.
1993.
Methods for antimicrobial susceptibility testing of anaerobic bacteria, 3rd ed. M11-A3
National Committee for Clinical Laboratory Standards, Villanova, Pa.
|
| 5.
|
Thompson, D. E.,
R. A. Huston,
A. K. East,
D. Allaway,
M. D. Collins, and P. T. Richardson.
1993.
Nucleotide sequence of the gene coding for Clostridium baratii type F neurotoxin: comparison with other clostridial neurotoxins.
FEMS Microbiol. Lett.
108:172-182.
|
| | | | |
G. Ravizzola
N. Manca
F. Dima
C. Signorini
E. Garrafa
A. Turano
Institute of Microbiology University of Brescia Spedali Civili Brescia, Italy
|
Journal of Clinical Microbiology, August 1998, p. 2396-2396, Vol. 36, No. 8
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.